Analysis InnoCan Pharma Corporation (INNPF)
6/3/2024
Analysis of InnoCan Pharma Corporation (INNPF)
InnoCan Pharma Corporation (symbol: INNPF) has shown some interesting price movements and technical indicators in the recent days:1. Price Movement:
- The closing price on May 31st was 0.20710, which remained the same as the opening price. The price has been relatively stable in the past few days.
2. Relative Strength Index (RSI):
- The RSI indicator on May 31st was 55.67, indicating a moderate level of buying momentum. This suggests that the stock is neither overbought nor oversold.
3. Moving Average Convergence Divergence (MACD):
- The MACD indicator was -0.00121 on May 31st, with the MACD line crossing above the signal line. This could signal a potential bullish trend in the short term.
4. Moving Averages (MA):
- The Simple Moving Average (SMA) on May 31st was 0.20198, the Exponential Moving Average (EMA) was 0.20519, and the Weighted Moving Average (WMA) was 0.20203. These moving averages can be used to identify potential support and resistance levels.
Overall, based on the technical indicators, InnoCan Pharma Corporation seems to be in a relatively stable position with some potential for a bullish trend in the short term. However, it is important to consider other factors such as market conditions and company news before making any investment decisions.
Earnings
The company's results for the most recent quarter ending on April 30, 2025, have not been provided at this time. The previous results were reported on February 27, 2025, through the Transfer Agent. Before that, on January 31, 2025, the results were released after hours. The results for October 31, 2024, were not provided at the time. On August 1, 2024, the company reported an earnings per share (EPS) estimate of 1.32.Main Statystic ðŸ§
The data provided includes financials, stock statistics, valuation metrics, stock price summary, and dividends and splits information for a specific company.In terms of financials, the company has strong cash flow with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet shows a total cash of $67.15 billion, total debt of $104.59 billion, and a current ratio of 1.037. The profit margin is 26.31% and the company's fiscal year ends on September 30, 2023. The income statement reveals an EBITDA of $131.39 billion, revenue of $381.62 billion, and a diluted EPS of 6.43.
Moving on to stock statistics, the company has a short ratio of 1.53, with 99.29 million shares shorted out of 15.31 billion float shares. The stock has an average 10-day volume of 46.86 million and an average 90-day volume of 57.50 million. The stock price summary includes a beta of 1.264, a 50-day moving average of $176.26, and a 200-day moving average of $181.04.
Valuation metrics show a PEG ratio of 26.32, forward PE ratio of 26.32, and trailing PE ratio of 29.59. The enterprise value is $2.95 trillion, with a price to book ratio of 39.34 and price to sales ratio of 7.65. The company's market capitalization is $2.92 trillion.
Lastly, dividends and splits information indicates a payout ratio of 14.93%, with a forward annual dividend rate of $1 and a forward annual dividend yield of 0.53%. The company's last split date was on August 31, 2020, with a 4-for-1 split factor.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential need for cost management strategies.
3. The gross profit margin has remained relatively stable over the years, indicating efficient cost control measures.
4. Operating income has shown a positive trend, reaching $114.3 billion in 2023 from $66.3 billion in 2020.
5. Net income has also been increasing consistently, from $57.4 billion in 2020 to $97 billion in 2023, showing a healthy growth in profitability.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally increased over the years, indicating growth in shareholder value.
7. The company has been able to maintain a stable number of outstanding shares, which is important for calculating financial ratios and metrics.
8. Overall, the financial performance of the company in terms of revenue and profitability has been positive and shows a growth trajectory.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets have fluctuated but generally increased, with the highest value in 2019 at $162,819,000,000.
3. Non-current assets have also shown an increasing trend, peaking at $234,386,000,000 in 2018.
4. Total liabilities have been increasing steadily, reaching $255,355,000,000 in 2018.
5. Current liabilities have also been on the rise, with the highest value in 2018 at $116,866,000,000.
6. Non-current liabilities have shown an increasing trend, peaking at $142,310,000,000 in 2019.
7. Shareholders' equity has generally increased over the years, with the highest value in 2018 at $107,147,000,000.
Cash Flow 💶
This is the cash flow statement. Here are some key takeaways:1. The company's free cash flow has been fluctuating over the years, with the highest value recorded in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. Financing activities show a pattern of common stock repurchases and long-term debt issuances, with significant variations in amounts each year.
4. Investing activities reflect a mix of acquisitions, capital expenditures, and investments, with notable changes in the sale and purchase of investments.
5. The end cash position has also varied, reaching its peak in 2020 and its lowest point in 2022.
6. Interest paid and income tax paid have shown fluctuations, impacting the company's overall cash flow position.
These insights provide a snapshot of the company's financial health and its management of cash flow over the past few years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share:1. For the current quarter ending on June 30, 2024, the average estimated EPS is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average estimated EPS is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This is also an increase from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average estimated EPS is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects growth compared to the EPS of $5.67 from the previous year.
4. For the next year ending on September 30, 2025, the average estimated EPS is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This indicates a slight increase from the EPS of $6.10 in the previous year.
Overall, the analysts' estimates suggest a positive outlook for the company's earnings per share, showing growth potential in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, the following conclusions can be drawn:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are forecasting moderate sales growth for both the upcoming quarters and the next fiscal year, with the highest growth expected in the next fiscal year ending in September 2025.
Growth estimates
Based on the consensus estimates provided, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slight increase in growth rate expected in the near future compared to the current period. However, the projected growth rates for the next year and the next 5 years are lower than the average growth rate achieved in the past 5 years.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $275, and the average forecast at $204.58. The current price of the security is $192.25, which is below the average and median forecasted prices. Investors should consider these forecasts along with other factors when making investment decisions.
MACD of INNPF
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
